Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct 15;3(1):e000231.
doi: 10.1136/tsaco-2018-000231. eCollection 2018.

Laboratory measures of coagulation among trauma patients on NOAs: results of the AAST-MIT

Affiliations

Laboratory measures of coagulation among trauma patients on NOAs: results of the AAST-MIT

Leslie M Kobayashi et al. Trauma Surg Acute Care Open. .

Abstract

Background: Warfarin is associated with poor outcomes after trauma, an effect correlated with elevations in the international normalized ratio (INR). In contrast, the novel oral anticoagulants (NOAs) have no validated laboratory measure to quantify coagulopathy. We sought to determine if use of NOAs was associated with elevated activated partial thromboplastin time (aPTT) or INR levels among trauma patients or increased clotting times on thromboelastography (TEG).

Methods: This was a post-hoc analysis of a prospective observational study across 16 trauma centers. Patients on dabigatran, rivaroxaban, or apixaban were included. Laboratory data were collected at admission and after reversal. Admission labs were compared between medication groups. Traditional measures of coagulopathy were compared with TEG results using Spearman's rank coefficient for correlation. Labs before and after reversal were also analyzed between medication groups.

Results: 182 patients were enrolled between June 2013 and July 2015: 50 on dabigatran, 123 on rivaroxaban, and 34 apixaban. INR values were mildly elevated among patients on dabigatran (median 1.3, IQR 1.1-1.4) and rivaroxaban (median 1.3, IQR 1.1-1.6) compared with apixaban (median 1.1, IQR 1.0-1.2). Patients on dabigatran had slightly higher than normal aPTT values (median 35, IQR 29.8-46.3), whereas those on rivaroxaban and apixaban did not. Fifty patients had TEG results. The median values for R, alpha, MA and lysis were normal for all groups. Prothrombin time (PT) and aPTT had a high correlation in all groups (dabigatran p=0.0005, rivaroxaban p<0.0001, and apixaban p<0.0001). aPTT correlated with the R value on TEG in patients on dabigatran (p=0.0094) and rivaroxaban (p=0.0028) but not apixaban (p=0.2532). Reversal occurred in 14%, 25%, and 18% of dabigatran, rivaroxaban, and apixaban patients, respectively. Both traditional measures of coagulopathy and TEG remained within normal limits after reversal.

Discussion: Neither traditional measures of coagulation nor TEG were able to detect coagulopathy in patients on NOAs.

Level of evidence: Level IV.

Keywords: anticoagulation; coagulation tests; trauma management.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 3
Figure 3
Correlation between aPTT and R values in patients on novel oral anticoagulants. TEGR, thromboelastogram Reaction (R) time; aPTT, activated partial thromboplastin time
Figure 1
Figure 1
Correlation between PT and aPTT values in patients on novel oral anticoagulants.
Figure 2
Figure 2
Correlation between PT and R values in patients on novel oral anticoagulants. TEGR, thromboelastogram Reaction (R) time; PT, prothrombin time

References

    1. Dossett LA, Riesel JN, Griffin MR, Cotton BA. Prevalence and implications of preinjury warfarin use: an analysis of the National Trauma Databank. Arch Surg 2011;146:565–70. 10.1001/archsurg.2010.313 - DOI - PubMed
    1. Maxwell CA, Miller RS, Dietrich MS, Mion LC, Minnick A. The aging of America: a comprehensive look at over 25,000 geriatric trauma admissions to United States hospitals. Am Surg 2015;81:630–6. - PubMed
    1. Siracuse JJ, Robich MP, Gautam S, Kasper EM, Moorman DW, Hauser CJ. Antiplatelet agents, warfarin, and epidemic intracranial hemorrhage. Surgery 2010;148:724–30. 10.1016/j.surg.2010.07.014 - DOI - PubMed
    1. Kirley K, Qato DM, Kornfield R, Stafford RS, Alexander GC. National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes 2012;5:615–21. 10.1161/CIRCOUTCOMES.112.967299 - DOI - PMC - PubMed
    1. Baglin T. Clinical use of new oral anticoagulant drugs: dabigatran and rivaroxaban. Br J Haematol 2013;163:160–7. 10.1111/bjh.12502 - DOI - PubMed